Article
Oncology
Esther N. Pijnappel, Nienke P. M. Wassenaar, Oliver J. Gurney-Champion, Remy Klaassen, Koen van der Lee, Marjolein C. H. Pleunis-van Empel, Dick J. Richel, Marie C. Legdeur, Aart J. Nederveen, Hanneke W. M. van Laarhoven, Johanna W. Wilmink
Summary: The combination of LDE225 with gemcitabine and nab-paclitaxel was well-tolerated and effective in patients with metastatic PDAC, especially in those with poor baseline tumor perfusion. These results suggest a potential clinical benefit of this combination therapy in patients who have received prior FOLFIRINOX treatment.
Article
Oncology
Tian-Yi Jiang, Xiao-Fan Feng, Zheng Fang, Xiao-Wen Cui, Yun-Kai Lin, Yu-Fei Pan, Chun Yang, Zhi-Wen Ding, Yong-Jie Zhang, Ye-Xiong Tan, Hong-Yang Wang, Li-Wei Dong
Summary: This study identified frequent alterations of PTEN in GBC, showing correlation with poor prognosis, and indicated proteasome inhibitor bortezomib as a promising therapeutic agent. Knockdown of PTEN increased bortezomib efficacy, and further evaluation using PDXs supported the utilization of bortezomib in PTEN-deficient GBC. Mechanistically, PTEN inhibited proteasome activity and bortezomib sensitivity through ARE-dependent transcriptional regulation, with involvement of the BACH1 transcriptional suppressor.
Article
Biochemistry & Molecular Biology
Kyota Ishii, Mayuko Hido, Misaki Sakamura, Nantiga Virgona, Tomohiro Yano
Summary: This study demonstrated that T3, TOS, and T3E enhance the sensitivity of the proteasome inhibitor BTZ in solid cancers by modulating the activity of NFE2L1. Inactivation of NFE2L1 by T3, TOS, and T3E is essential to potentiate the cytotoxic effect of BTZ in solid cancers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Chemistry, Multidisciplinary
Mingyu Chen, Sarun Juengpanich, Shijie Li, Win Topatana, Ziyi Lu, Qiang Zheng, Jiasheng Cao, Jiahao Hu, Esther Chan, Lidan Hou, Jiang Chen, Fang Chen, Yu Liu, Sukanda Jiansirisomboon, Zhen Gu, Suparat Tongpeng, Xiujun Cai
Summary: This study reports on a targeted therapy for gallbladder cancer using pH-responsive nanoparticles encapsulating bortezomib and mediated by estrogen-induced endocytosis. The treatment effectively inhibits proteasomes and induces apoptosis under tumor microenvironment and laser irradiation.
Article
Multidisciplinary Sciences
Mengmeng Dong, Jinna Zhang, Xiaoyan Han, Jingsong He, Gaofeng Zheng, Zhen Cai
Summary: This study retrospectively analyzed clinical data of 155 MM patients and found that baseline PN was age-related, leading to more severe BiPN during bortezomib induction therapy and worse PN outcome after induction therapy. MM patients with baseline PN also had worse PFS and OS.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Andrea E. Wahner Hendrickson, Daniel W. Visscher, Xiaonan Hou, Krista M. Goergen, Hunter J. Atkinson, Thomas G. Beito, Vivian Negron, Wilma L. Lingle, Amy K. Bruzek, Rachel M. Hurley, Jill M. Wagner, Karen S. Flatten, Kevin L. Peterson, Paula A. Schneider, Melissa C. Larson, Matthew J. Maurer, Kimberly R. Kalli, Ann L. Oberg, S. John Weroha, Scott H. Kaufmann
Summary: Studies have shown that CHFR levels vary among ovarian cancers but are unlikely to be an independent biomarker for poor response to taxanes. Additionally, CHFR expression is not significantly associated with overall survival or time to progression in high grade serous ovarian cancer patients treated with platinum/taxane chemotherapy. Furthermore, there is no observed association between CHFR expression and paclitaxel sensitivity in patient-derived ovarian cancer xenografts.
Article
Pharmacology & Pharmacy
Wilhelm Flat, Sarah Borowski, Themistoklis Paraschiakos, Christine Blechner, Sabine Windhorst
Summary: High DIAPH1 levels are correlated with increased survival of ovarian cancer patients. Down-regulation of DIAPH1 expression decreases PTX sensitivity and reduces the concentration of stable microtubules. In addition, DIAPH1 enhances the effect of PTX on microtubule stability in a cell-free system. Thus, DIAPH1 increases the response of Ovca cells to PTX.
BIOCHEMICAL PHARMACOLOGY
(2022)
Review
Oncology
Ramon Yarza, Mateo Bover, Maria Teresa Agullo-Ortuno, Lara Carmen Iglesias-Docampo
Summary: Nasopharyngeal carcinoma (NPC) is a molecularly paradigmatic tumor with complex environmental and host dependent factors, where Epstein Barr Virus (EBV) plays a key role in malignant transformation. The dysregulation of proteasome signaling is central in NPC pathogenesis and could be a potential therapeutic target. Studies have shown the efficacy of immunotherapy in NPC, with novel strategies aiming to reverse immune resistance and favor tumor recognition.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Chemistry, Medicinal
Markus Klein, Michael Busch, Manja Friese-Hamim, Stefano Crosignani, Thomas Fuchss, Djordje Musil, Felix Rohdich, Michael P. Sanderson, Jeyaprakashnarayanan Seenisamy, Gina Walter-Bausch, Ugo Zanelli, Philip Hewitt, Christina Esdar, Oliver Schadt
Summary: Proteasomes are essential components of the ubiquitin-dependent protein degradation pathway, with LMP7 being a subunit of the immunoproteasome. Current pan-proteasome inhibitors nonselectively target LMP7 and other subunits, limiting their therapeutic applicability. Novel amido boronic acids were discovered to selectively inhibit LMP7, leading to the identification of the highly potent and orally available inhibitor M3258, which showed strong antitumor activity in MM models.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Biochemistry & Molecular Biology
Zohreh Jahani, Jamshid Davoodi
Summary: Metformin, an anti-diabetic drug, has a dual effect on breast cancer cell lines by both upregulating and enhancing the degradation of certain proteins during mTORC1 inhibition.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Review
Biochemistry & Molecular Biology
Jianhao Liu, Ruogang Zhao, Xiaowen Jiang, Zhaohuan Li, Bo Zhang
Summary: Bortezomib is a proteasome inhibitor that has been approved for the treatment of multiple myeloma and other hematological cancers. However, its limited specificity, poor permeability, and low bioavailability hinder its applications. Recent research has focused on the development of BTZ-based drug delivery systems.
Review
Immunology
Naeemeh Khalesi, Shahla Korani, Mitra Korani, Thomas P. Johnston, Amirhossein Sahebkar
Summary: Autoimmune diseases are conditions where the immune system cannot distinguish self from non-self, leading to tissue injury. The proteasome inhibitor bortezomib has shown effectiveness in treating patients with ADs resistant to conventional therapies.
INFLAMMOPHARMACOLOGY
(2021)
Article
Materials Science, Biomaterials
Qiaoying Wang, Changqiang Wu, Xiaoting Li, Dixiao Yang, Liangjun Shi
Summary: The study developed an effective drug delivery system using biocompatible polymer mPEG-PAsp for co-loading chemotherapy drugs PTX and CP, which demonstrated synergistic anti-tumor efficacy. The results suggested that mPEG-PAsp nano-micelles are promising alternatives for carrying and improving the delivery of therapeutic drugs with different water solubilities.
REGENERATIVE BIOMATERIALS
(2021)
Article
Materials Science, Biomaterials
Liqin Cao, Huiyao Gu, Zhaowenbing Zhang, Enfan Zhang, Jiang Chang, Zhen Cai
Summary: Multiple myeloma is a common hematologic malignancy and the current treatment with Bortezomib often leads to drug resistance and side effects. The study shows that calcium silicate enhances the anti-myeloma effect of Bortezomib and suggests that this combination could be a promising strategy to overcome drug resistance in multiple myeloma.
JOURNAL OF MATERIALS CHEMISTRY B
(2023)
Review
Oncology
Azmi Yerlikaya, Ertan Kanbur, Bruce A. Stanley, Emrah Tumer
Summary: The ubiquitin-proteasome pathway is involved in almost all cellular processes and recent studies indicate that epigenetic changes are also regulated by this pathway. Alterations in the regulation of the ubiquitin-proteasome pathway have been discovered in many pathological conditions, and the interaction between the ubiquitin-proteasome and epigenetic pathways may offer new treatment strategies for cancer.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
(2021)
Article
Oncology
Elizabeth H. Kerr, Peter J. Frederick, Michael E. Egger, Cecil R. Stockard, Jeffery Sellers, Debbie DellaManna, Denise K. Oelschlager, Hope M. Amm, Isam-Eldin Eltoum, J. Michael Straughn, Donald J. Buchsbaum, William E. Grizzle, Lacey R. McNally
ANNALS OF SURGICAL ONCOLOGY
(2013)
Article
Anatomy & Morphology
C. Ren, M. G. Diniz, C. Piazza, H. M. Amm, D. L. Rollins, H. Rivera, P. Devilliers, D. P. Kestler, P. D. Waite, O. A. Mamaeva, M. MacDougall
CELLS TISSUES ORGANS
(2011)
Article
Cell Biology
Hope M. Amm, Monee D. Casimir, Dakota B. Clark, Phillip Sohn, Mary MacDougall
CONNECTIVE TISSUE RESEARCH
(2014)
Article
Cell Biology
Changming Lu, Olga A. Mamaeva, Chun Cui, Hope Amm, Frank Rutsch, Mary MacDougall
CONNECTIVE TISSUE RESEARCH
(2014)
Review
Oncology
Hope M. Amm, Donald J. Buchsbaum
EXPERT REVIEW OF ANTICANCER THERAPY
(2011)
Article
Oncology
Kerri S. Bevis, Lacey R. McNally, Jeffery C. Sellers, Deborah Della Manna, Angelina Londono Joshi, Hope Amm, J. Michael Straughn, Donald J. Buchsbaum
GYNECOLOGIC ONCOLOGY
(2011)
Article
Biochemistry & Molecular Biology
Changchun Ren, Hope M. Amm, Patricia DeVilliers, Yixin Wu, Joseph R. Deatherage, Zhongyu Liu, Mary MacDougall
JOURNAL OF BIOLOGICAL CHEMISTRY
(2012)
Article
Dentistry, Oral Surgery & Medicine
Hope M. Amm, Douglas L. Rollins, Changchun Ren, Juan Dong, Patricia DeVilliers, Helen Rivera, Mary MacDougall
JOURNAL OF ORAL PATHOLOGY & MEDICINE
(2014)
Article
Oncology
Marina Goncalves Diniz, Carolina Cavalieri Gomes, Wagner Henriques de Castro, Andre Luiz Sena Guimaraes, Alfredo Mauricio Batista De Paula, Hope Amm, Chanchung Ren, Mary MacDougall, Ricardo Santiago Gomez
Article
Dentistry, Oral Surgery & Medicine
Anthony B. Morlandt, Lindsay S. Moore, Aubrey O. Johnson, Caris M. Smith, Todd M. Stevens, Jason M. Warram, Mary MacDougall, Eben L. Rosenthal, Hope M. Amm
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
(2020)
Article
Oncology
Tiara S. Napier, Neha Udayakumar, Aditi H. Jani, Yolanda E. Hartman, Hailey A. Houson, Lindsay Moore, Hope M. Amm, Nynke S. van den Berg, Anna G. Sorace, Jason M. Warram
MOLECULAR CANCER THERAPEUTICS
(2020)
Review
Oncology
Burthia E. Booker, Adam D. Steg, Stefan Kovac, Charles N. Landen, Hope M. Amm
CANCER BIOLOGY & THERAPY
(2020)
Article
Multidisciplinary Sciences
Logan D. Stone, Adriana V. F. Massicano, Todd M. Stevens, Jason M. Warram, Anthony B. Morlandt, Suzanne E. Lapi, Hope M. Amm
Summary: Accurate assessment of tumor margins using non-invasive imaging is crucial for preserving healthy tissue and improving long-term tumor control. This study investigates the use of epidermal growth factor receptor (EGFR) as an imaging biomarker for ameloblastomas. The results show that radiolabeled anti-EGFR exhibits specificity for ameloblastoma PDX tumor xenografts, making it a promising target for pre-surgical imaging. This technology could enhance the accuracy of tumor margin assessment for the surgical removal of ameloblastomas.
SCIENTIFIC REPORTS
(2022)
Article
Dentistry, Oral Surgery & Medicine
Hope M. Amm, Patricia DeVilliers, Ambika R. Srivastava, Marina G. Diniz, Gene P. Siegal, Mary MacDougall
CLINICAL AND EXPERIMENTAL DENTAL RESEARCH
(2020)